PeptideDB

NBQX Disodium

CAS No.: 479347-86-9

NBQX Disodium (FG9202 disodium) is a highly selective, competitive AMPA receptor antagonist with neuroprotective and ant
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description NBQX Disodium (FG9202 disodium) is a highly selective, competitive AMPA receptor antagonist with neuroprotective and anticonvulsant activity. NBQX Disodium is a salt of NBQX. NBQX is a potent and selective AMPA/rhodosinate receptor antagonist that can be used to antagonize the excitatory toxicity of glutamate. It has anticonvulsant effects in rodent models.
In vitro 在HIP-009细胞中,NBQX Disodium 以浓度依赖的方式抑制了由AMPA或者羟基乳酸(KA)诱导的信号,IC50值分别为0.7 ± 0.1 μM 和0.7 ± 0.03 μM。NBQX Disodium 完全抑制了AMPA引起的钙上升,而NBQX Disodium 30 μM处理对KA诱导的信号抑制了68.6% ± 1.3%。[1]
In vivo NBQX disodium (FG9202; 20 mg/kg, i.p.; 连续3天)管理能够降低PTZ引发的癫痫发作。[2] 在大鼠局部缺血模型中, NBQX disodium 通过在MCA阻塞时静脉注射一次性剂量30 mg/kg,并在阻塞后1小时再次注射,展现出神经保护效果。[3]
Target activity AMPA:0.7 ± 0.1 μM, Kainic acid:0.7 ± 0.03 μM
Synonyms FG9202 disodium, NBQX 2Na
molecular weight 380.24
Molecular formula C12H6N4Na2O6S
CAS 479347-86-9
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility H2O: 34.2 mg/mL (90.0 mM), Sonication is recommended.
References 1. Fukushima K, et al. Characterization of Human Hippocampal Neural Stem/Progenitor Cells and Their Application to Physiologically Relevant Assays for Multiple Ionotropic Glutamate Receptors. J Biomol Screen. 2014;19(8):1174-1184. 2. Chen W, et al. AMPA Receptor Antagonist NBQX Decreased Seizures by Normalization of Perineuronal Nets. PLoS One. 2016;11(11):e16667 3. T001 4. Twele F, et al. The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy. Neuropharmacology. 2015;95:234-242. 5. Ruda-Kucerova J, et al. NBQX attenuates relapse of nicotine seeking but not nicotine and methamphetamine self-administration in rats. World J Biol Psychiatry. 2021;22(10):733-743.